Triplebar CEO and prominent business leader Maria Cho will take the stage at the Biotech Showcase in San Francisco on 14 January to unveil, among several other major game-changing breakthroughs, her company’s ability to develop a GPT-4-sized genomic AI in a fraction of the time and cost of traditional methods.
Cho will also illustrate how Triplebar’s technology can reduce the time required to build the predictive genomic language model by over 90%. This means it can achieve that in a year instead of the ten-plus years it currently takes.
“Thanks to our unique microprocessor, we generate massive genomic datasets that are functionally labeled to fuel AI and ML models, transforming cell line protein secretion from a decade-long endeavor into a ten-day reality with actionable commercial metrics,” she added.
Triplebar is today at the forefront of revolutionary efficiency in biology technology, cost-effectiveness, and scalability of their platform, which directly translates into a competitive advantage in multiple high-value markets like biologics, AI-driven drug discovery, and personalized medicine.
“Our Evolutionary Intelligence will redefine the biotech landscape, unlocking unparalleled opportunities in biologics and personalized medicine,” said Cho.
Its collaboration with Google DeepMind, Triplebar, and Deepmind demonstrated the application of machine learning to massive functional datasets, highlighting Triplebar’s forward-thinking approach. Triplebar has an unmatched dataset generation capability, offering it a significant competitive edge.
The microfluidics platform is akin to the transformative microprocessors in computing, positioning Triplebar in a unique position within its industry regarding scalability, speed, and revolutionary change in how biotech problems are approached.
The San Francisco-based startup is leveraging the potential synergies of AI and biology and strengthening its ability to generate sustained value across several industries and applications — from therapeutics to food production.
Cho will also reveal details about the consortium Triplebar is forming across the manufacturing value chain to create the next generation of CHO production cell lines and other projects that aim to disrupt the traditional drug discovery and biologics production pipelines with a clear path to commercialization.
Throughout her presentation, Cho will present Triplebar’s evolutionary intelligence and how it addresses critical needs across multi-billion-dollar markets, from personalized cancer therapies to scalable biologics production.
The Biotech Showcase is one of the largest and most influential investor conferences, alongside JP Morgan’s annual Healthcare conference for private and biotechnology companies. It gives startups and companies the unique opportunity to showcase their game-changing innovations.